

Sandhya Bangaru

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1434386/sandhya-bangaru-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

1,534
citations

14
h-index

28
g-index

28
ext. papers

2,151
ext. citations

18.7
avg, IF

4.55
L-index

#	Paper	IF	Citations
27	Structural mapping of antibody landscapes to human betacoronavirus spike proteins.. <i>Science Advances</i> , 2022 , 8, eabn2911	14.3	1
26	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants 2021 ,		6
25	Structure and immune recognition of the porcine epidemic diarrhea virus spike protein. <i>Structure</i> , 2021 , 29, 385-392.e5	5.2	13
24	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021 , 29, 806-818.e6	23.4	24
23	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection 2021 ,		3
22	Human antibody recognition of H7N9 influenza virus HA following natural infection. <i>JCI Insight</i> , 2021 , 6,	9.9	1
21	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect in a Mouse Model in a Neutralization-Dependent Manner. <i>MBio</i> , 2021 , 12, e0100221	7.8	2
20	Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	4
19	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021 , 13, eabj5413	17.5	18
18	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020 , 369, 643-650	33.3	724
17	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <i>PLoS Pathogens</i> , 2020 , 16, e1009089	7.6	33
16	An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain 2020 ,		8
15	Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity 2020 ,		13
14	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate 2020 ,		8
13	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody 2020 ,		2
12	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. <i>Science</i> , 2020 , 370, 1089-1094	33.3	153
11	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. <i>Cell Reports</i> , 2020 , 33, 108274	10.6	107

10	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. <i>Immunity</i> , 2020 , 53, 1272-1280.e5	32.3	112
9	Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. <i>PLoS Biology</i> , 2019 , 17, e3000139	9.7	26
8	A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. <i>Cell</i> , 2019 , 177, 1136-1152.e18	56.2	107
7	Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. <i>Cell Host and Microbe</i> , 2019 , 26, 729-738.e4	23.4	29
6	Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. <i>Cell Host and Microbe</i> , 2019 , 26, 715-728.e8	23.4	30
5	A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. <i>Nature Communications</i> , 2018 , 9, 2669	17.4	44
4	Recognition of influenza H3N2 variant virus by human neutralizing antibodies. <i>JCI Insight</i> , 2016 , 1,	9.9	17
3	H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1482-94	15.9	46
2	Structure and immune recognition of the porcine epidemic diarrhea virus spike protein		2
1	Structural mapping of antibody landscapes to human betacoronavirus spike proteins		1